NO326170B1 - Krystallinske former av Atorvastatin - Google Patents

Krystallinske former av Atorvastatin Download PDF

Info

Publication number: NO326170B1
Authority: NO; Norway
Prior art keywords: atorvastatin; wide; crystalline form; ray powder; powder diffraction
Prior art date: 2001-06-29

Application number

NO20035675A

Other languages

English (en)

Norwegian (no)

Other versions

NO20035675D0 (no

Inventor

Stephen Robert Byrn

Aeri Park

David Andrew Coates

Karen Sue Gushurst

Ii Henry Grant Morrison

Petinka Ivanova Vlahova

Joseph Francis Krzyzaniak

Jane Li

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-29

Filing date

2003-12-18

Publication date

2008-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23166039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326170(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-18 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2003-12-18 Publication of NO20035675D0 publication Critical patent/NO20035675D0/no

2008-10-13 Publication of NO326170B1 publication Critical patent/NO326170B1/no

Links

XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims description 195
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims description 195
229960005370 atorvastatin Drugs 0.000 title claims description 195
238000000634 powder X-ray diffraction Methods 0.000 claims description 63
230000005855 radiation Effects 0.000 claims description 50
229910016523 CuKa Inorganic materials 0.000 claims description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 36
229960001770 atorvastatin calcium Drugs 0.000 description 36
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
238000000034 method Methods 0.000 description 31
150000004677 hydrates Chemical class 0.000 description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
150000001875 compounds Chemical class 0.000 description 23
239000000243 solution Substances 0.000 description 20
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
238000001237 Raman spectrum Methods 0.000 description 15
239000007790 solid phase Substances 0.000 description 15
239000000126 substance Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 11
239000000843 powder Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000002775 capsule Substances 0.000 description 10
238000002844 melting Methods 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
238000000113 differential scanning calorimetry Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
150000004684 trihydrates Chemical class 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
238000001035 drying Methods 0.000 description 6
239000012453 solvate Substances 0.000 description 6
239000013543 active substance Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000009987 spinning Methods 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 4
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 4
238000002441 X-ray diffraction Methods 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000003524 antilipemic agent Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
239000003529 anticholesteremic agent Substances 0.000 description 3
238000009838 combustion analysis Methods 0.000 description 3
238000012937 correction Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000004807 desolvation Methods 0.000 description 3
150000004683 dihydrates Chemical class 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000000055 hyoplipidemic effect Effects 0.000 description 3
231100001231 less toxic Toxicity 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000009897 systematic effect Effects 0.000 description 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
238000003109 Karl Fischer titration Methods 0.000 description 2
238000001069 Raman spectroscopy Methods 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
238000005384 cross polarization magic-angle spinning Methods 0.000 description 2
238000013480 data collection Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002411 thermogravimetry Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
241000792859 Enema Species 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
238000005004 MAS NMR spectroscopy Methods 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
-1 [R-(R<*> Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
229910001573 adamantine Inorganic materials 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
JNDMLEXHDPKVFC-UHFFFAOYSA-N aluminum;oxygen(2-);yttrium(3+) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Y+3] JNDMLEXHDPKVFC-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004164 analytical calibration Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004687 hexahydrates Chemical class 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940002661 lipitor Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229910019655 synthetic inorganic crystalline material Inorganic materials 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20035675A 2001-06-29 2003-12-18 Krystallinske former av Atorvastatin NO326170B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30204901P	2001-06-29	2001-06-29
PCT/IB2002/001796 WO2003004470A1 (fr)	2001-06-29	2002-05-21	Formes cristallines de sel hemicalcique d'acide [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (atorvastatine)

Publications (2)

Publication Number	Publication Date
NO20035675D0 NO20035675D0 (no)	2003-12-18
NO326170B1 true NO326170B1 (no)	2008-10-13

Family

ID=23166039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20035675A NO326170B1 (no)	2001-06-29	2003-12-18	Krystallinske former av Atorvastatin

Country Status (40)

Country	Link
US (5)	US6605729B1 (fr)
EP (2)	EP3009423A3 (fr)
JP (2)	JP3965155B2 (fr)
KR (1)	KR100609371B1 (fr)
CN (2)	CN101215253A (fr)
AP (1)	AP1571A (fr)
AR (1)	AR036118A1 (fr)
AU (1)	AU2002258092B2 (fr)
BG (1)	BG108393A (fr)
BR (1)	BR0210666A (fr)
CA (1)	CA2450111C (fr)
CR (2)	CR7170A (fr)
CZ (1)	CZ20033478A3 (fr)
DO (1)	DOP2002000413A (fr)
EA (1)	EA005317B1 (fr)
EC (1)	ECSP034928A (fr)
EE (1)	EE200300597A (fr)
ES (1)	ES2558565T3 (fr)
GE (1)	GEP20053546B (fr)
HR (1)	HRP20031039A2 (fr)
HU (1)	HUP0400381A2 (fr)
IL (1)	IL158790A0 (fr)
MA (1)	MA27044A1 (fr)
MX (1)	MXPA03010266A (fr)
MY (1)	MY122907A (fr)
NO (1)	NO326170B1 (fr)
NZ (1)	NZ529557A (fr)
OA (1)	OA12636A (fr)
PA (1)	PA8549501A1 (fr)
PE (1)	PE20030124A1 (fr)
PL (1)	PL367943A1 (fr)
RS (1)	RS100003A (fr)
SK (1)	SK16002003A3 (fr)
SV (1)	SV2003001144A (fr)
TN (1)	TNSN03147A1 (fr)
TW (1)	TWI319396B (fr)
UA (1)	UA74075C2 (fr)
UY (1)	UY27359A1 (fr)
WO (1)	WO2003004470A1 (fr)
ZA (1)	ZA200308731B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IL128864A (en)	1995-07-17	2007-10-31	Warner Lambert Co	Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
US20040072138A1 (en) *	1997-11-25	2004-04-15	Medical University Of South Carolina	Attenuation of ischemia/reperfusion injury
US20080275104A1 (en) *	1997-11-25	2008-11-06	Musc Foundation For Research Development	Methods of treating juvenile type 1 diabetes mellitus
WO1999026657A1 (fr) *	1997-11-25	1999-06-03	Musc Foundation For Research Development	Inhibiteurs de la monoxyde d'azote-synthase
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
AU4150602A (en) *	2000-11-03	2002-06-03	Teva Pharma	Atorvastatin hemi-calcium form vii
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) *	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'atorvastatine
MXPA03010266A (es) *	2001-06-29	2004-03-10	Warner Lambert Co	Formas cristalinas de la sal de calcio del acido [r-(r, r)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
US7074818B2 (en) *	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) *	2001-11-29	2006-01-26	Limor Tessler	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
HRP20040768A2 (en) *	2002-02-15	2005-06-30	Teva Pharmaceutical Industries Ltd.	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
PL372241A1 (en) *	2002-02-19	2005-07-11	Teva Pharmaceutical Industries Ltd.	Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
EP1562583A1 (fr) *	2002-09-03	2005-08-17	Morepen Laboratories Ltd.	Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
CA2508871C (fr) *	2002-11-28	2008-09-09	Teva Pharmaceutical Industries Ltd.	Forme cristalline f de sel d'hemi-calcium d'astorvastatine
US7790197B2 (en) *	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
US7655692B2 (en) *	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
CA2548313A1 (fr) *	2003-12-23	2005-07-14	Musc Foundation For Research Development	Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
EP1761489A1 (fr) *	2004-03-17	2007-03-14	Ranbaxy Laboratories Limited	Forme cristalline d'hemi-calcium d'atorvastatine
EP1577297A1 (fr)	2004-03-17	2005-09-21	Ranbaxy Laboratories, Ltd.	Procede de production d'atorvastatine calcique sous forme amorphe
BRPI0510713A (pt)	2004-05-05	2007-11-20	Pfizer Prod Inc	formas de sal de ácido [r-(r,r)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
CA2754932C (fr)	2004-07-20	2014-04-01	Warner-Lambert Company Llc	Nouvelles formes de [r-(r,r)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
CN101124230A (zh) *	2004-09-28	2008-02-13	特瓦制药工业有限公司	制备基本无杂质的阿托伐他汀钙形式的方法
EP1807055A1 (fr) *	2004-10-28	2007-07-18	Warner-Lambert Company LLC	Procede de formation d'atorvastatine amorphe
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
WO2006054308A2 (fr) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
WO2006059224A1 (fr) *	2004-12-02	2006-06-08	Warner-Lambert Company Llc	Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
EP1688850A1 (fr)	2005-02-07	2006-08-09	Sony Ericsson Mobile Communications AB	Analyseur générique pour les dispositifs électroniques
US8506646B2 (en) *	2005-04-29	2013-08-13	Warsaw Orthopedic, Inc.	Multi-purpose medical implant devices
US8092464B2 (en) *	2005-04-30	2012-01-10	Warsaw Orthopedic, Inc.	Syringe devices and methods useful for delivering osteogenic material
EP1923057A1 (fr) *	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Formule pharmaceutique atorvastanine
DK1957452T3 (da)	2005-11-21	2010-07-26	Warner Lambert Co	Nye former af [R-(R,R)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
KR20080079646A (ko) *	2005-11-21	2008-09-01	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴 제제
MX2007014329A (es) *	2005-12-13	2008-03-19	Teva Pharma	Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US7834195B2 (en) *	2007-01-24	2010-11-16	Apotex Pharmachem Inc.	Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko)	2007-01-29	2009-01-12	한미약품 주식회사	아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
JP2010520273A (ja) *	2007-03-02	2010-06-10	ドン・ア・ファーム・カンパニー・リミテッド	ピロリルヘプタン酸誘導体の新規な結晶形態
US20080227846A1 (en) *	2007-03-13	2008-09-18	Musc Foundation For Research Development	Methods of treating juvenile type 1 diabetes mellitus
WO2008123953A1 (fr) *	2007-04-02	2008-10-16	Merck & Co., Inc.	Composé anti-hypercholestérolémique
DE102007052071A1 (de)	2007-10-30	2009-05-07	Stada Arzneimittel Ag	Stabilisiertes Atorvastatin
CN101973922B (zh) *	2009-05-27	2013-01-23	天津和美生物技术有限公司	阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
US9334266B2 (en)	2009-09-04	2016-05-10	The University Of Toledo	Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
CZ201039A3 (cs)	2010-01-19	2011-07-27	Zentiva, K. S	Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) *	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US20140335179A1 (en) *	2011-07-01	2014-11-13	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Micronized crystals of atorvastatin hemicalcium
CN104945300B (zh) *	2015-06-17	2017-05-10	北京嘉林药业股份有限公司	一种ⅰ型阿托伐他汀钙的纯化方法
CN104983702A (zh) *	2015-07-23	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
US10450957B2 (en)	2017-01-23	2019-10-22	United Technologies Corporation	Gas turbine engine with heat pipe system
KR20200054910A (ko)	2017-04-18	2020-05-20	젬파이어 세러퓨틱스 인코포레이티드	젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법
JPWO2020013330A1 (ja) *	2018-07-13	2021-06-24	協和発酵バイオ株式会社	ユーコミン酸の非溶媒和物結晶及びその製造方法
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en)	1990-10-17	1993-09-28	Warner-Lambert Company	Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DE69324504T2 (de)	1993-01-19	1999-08-26	Warner-Lambert Co.	Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128864A (en)	1995-07-17	2007-10-31	Warner Lambert Co	Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
HRP960312B1 (en) *	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en)	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DK0915866T3 (da)	1996-07-29	2002-06-10	Warner Lambert Co	Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
IN191236B (fr) *	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
DE60044884D1 (de) *	1999-11-17	2010-10-07	Teva Pharma	Verfahren zur Herstellung einer polymorphen Form von Atorvastatin calcium
SI20425A (sl)	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
MXPA02004082A (es) *	1999-12-17	2002-10-11	Warner Lambert Res & Dev	Un proceso para producir calcio de atorvastatin cristalino.
WO2001044180A1 (fr) *	1999-12-17	2001-06-21	Warner Lambert Research And Development Ireland Limited	Procede de production a l'echelle industrielle de sel d'hemi-calcium trihydrate d'atorvastatine cristallise
AU4150602A (en) *	2000-11-03	2002-06-03	Teva Pharma	Atorvastatin hemi-calcium form vii
HUP0303555A3 (en) *	2000-11-16	2005-08-29	Teva Pharma	Hydrolysis of [r(r
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) *	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) *	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'atorvastatine
WO2002057228A1 (fr)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatine calcique
WO2002057229A1 (fr)	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl)	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
GB0111077D0 (en)	2001-05-04	2001-06-27	Biochemie Gmbh	Organic compounds
MXPA03010266A (es) *	2001-06-29	2004-03-10	Warner Lambert Co	Formas cristalinas de la sal de calcio del acido [r-(r, r)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
US7074818B2 (en) *	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
MX2007014329A (es) *	2005-12-13	2008-03-19	Teva Pharma	Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

2002
- 2002-05-21 MX MXPA03010266A patent/MXPA03010266A/es active IP Right Grant
- 2002-05-21 HR HR20031039A patent/HRP20031039A2/xx not_active Application Discontinuation
- 2002-05-21 OA OA1200300342A patent/OA12636A/en unknown
- 2002-05-21 CZ CZ20033478A patent/CZ20033478A3/cs unknown
- 2002-05-21 AP APAP/P/2003/002936A patent/AP1571A/en active
- 2002-05-21 WO PCT/IB2002/001796 patent/WO2003004470A1/fr not_active Ceased
- 2002-05-21 NZ NZ529557A patent/NZ529557A/en unknown
- 2002-05-21 GE GE5360A patent/GEP20053546B/en unknown
- 2002-05-21 CN CNA2007101598559A patent/CN101215253A/zh active Pending
- 2002-05-21 EE EEP200300597A patent/EE200300597A/xx unknown
- 2002-05-21 AU AU2002258092A patent/AU2002258092B2/en not_active Ceased
- 2002-05-21 CA CA002450111A patent/CA2450111C/fr not_active Expired - Fee Related
- 2002-05-21 KR KR1020037016944A patent/KR100609371B1/ko not_active Expired - Fee Related
- 2002-05-21 JP JP2003510638A patent/JP3965155B2/ja not_active Expired - Fee Related
- 2002-05-21 ES ES02727946.2T patent/ES2558565T3/es not_active Expired - Lifetime
- 2002-05-21 IL IL15879002A patent/IL158790A0/xx unknown
- 2002-05-21 UA UA20031212658A patent/UA74075C2/uk unknown
- 2002-05-21 SK SK1600-2003A patent/SK16002003A3/sk unknown
- 2002-05-21 BR BR0210666-3A patent/BR0210666A/pt not_active IP Right Cessation
- 2002-05-21 EA EA200301243A patent/EA005317B1/ru not_active IP Right Cessation
- 2002-05-21 RS YUP-1000/03A patent/RS100003A/sr unknown
- 2002-05-21 HU HU0400381A patent/HUP0400381A2/hu unknown
- 2002-05-21 CN CNA028130227A patent/CN1524073A/zh active Pending
- 2002-05-21 PL PL02367943A patent/PL367943A1/xx not_active Application Discontinuation
- 2002-05-21 EP EP15192682.1A patent/EP3009423A3/fr not_active Withdrawn
- 2002-05-21 EP EP02727946.2A patent/EP1423364B1/fr not_active Expired - Lifetime
- 2002-06-05 DO DO2002000413A patent/DOP2002000413A/es unknown
- 2002-06-26 PE PE2002000569A patent/PE20030124A1/es not_active Application Discontinuation
- 2002-06-27 UY UY27359A patent/UY27359A1/es not_active Application Discontinuation
- 2002-06-28 PA PA20028549501A patent/PA8549501A1/es unknown
- 2002-06-28 SV SV2002001144A patent/SV2003001144A/es not_active Application Discontinuation
- 2002-06-28 TW TW091114336A patent/TWI319396B/zh not_active IP Right Cessation
- 2002-06-28 AR ARP020102428A patent/AR036118A1/es unknown
- 2002-06-28 MY MYPI20022466A patent/MY122907A/en unknown
- 2002-06-28 US US10/184,669 patent/US6605729B1/en not_active Expired - Lifetime
2003
- 2003-06-06 US US10/456,046 patent/US7144915B2/en not_active Expired - Lifetime
- 2003-07-08 TN TNPCT/IB2002/001796A patent/TNSN03147A1/fr unknown
- 2003-11-10 ZA ZA200308731A patent/ZA200308731B/en unknown
- 2003-11-26 CR CR7170A patent/CR7170A/es not_active Application Discontinuation
- 2003-11-28 BG BG108393A patent/BG108393A/bg unknown
- 2003-12-18 NO NO20035675A patent/NO326170B1/no unknown
- 2003-12-22 MA MA27456A patent/MA27044A1/fr unknown
- 2003-12-29 EC EC2003004928A patent/ECSP034928A/es unknown
2006
- 2006-05-25 US US11/441,268 patent/US20060241169A1/en not_active Abandoned
2007
- 2007-04-11 JP JP2007103465A patent/JP2007182460A/ja active Pending
- 2007-10-25 US US11/977,459 patent/US20080214651A1/en not_active Abandoned
2008
- 2008-02-15 CR CR9741A patent/CR9741A/es not_active Application Discontinuation
- 2008-07-14 US US12/172,503 patent/US20080287521A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PA8549501A1 (es)	2003-09-05
GEP20053546B (en)	2005-06-10
EP3009423A2 (fr)	2016-04-20
ECSP034928A (es)	2004-02-26
CA2450111C (fr)	2006-02-07
EA200301243A1 (ru)	2004-06-24
BR0210666A (pt)	2004-10-05
NZ529557A (en)	2005-05-27
CR9741A (es)	2008-10-31
DOP2002000413A (es)	2003-07-15
CZ20033478A3 (cs)	2004-10-13
EP3009423A3 (fr)	2016-12-28
EP1423364A1 (fr)	2004-06-02
TWI319396B (en)	2010-01-11
CA2450111A1 (fr)	2003-01-16
AP1571A (en)	2006-02-10
WO2003004470A1 (fr)	2003-01-16
US6605729B1 (en)	2003-08-12
EA005317B1 (ru)	2004-12-30
AU2002258092B2 (en)	2007-05-17
CR7170A (es)	2004-02-23
MXPA03010266A (es)	2004-03-10
MA27044A1 (fr)	2004-12-20
HRP20031039A2 (en)	2005-10-31
UY27359A1 (es)	2003-04-30
US20080287521A1 (en)	2008-11-20
JP2005501032A (ja)	2005-01-13
CN1524073A (zh)	2004-08-25
EE200300597A (et)	2004-02-16
IL158790A0 (en)	2004-05-12
ES2558565T3 (es)	2016-02-05
KR100609371B1 (ko)	2006-08-08
BG108393A (bg)	2004-12-30
EP1423364B1 (fr)	2015-11-04
RS100003A (sr)	2007-02-05
HUP0400381A2 (hu)	2004-09-28
JP3965155B2 (ja)	2007-08-29
MY122907A (en)	2006-05-31
ZA200308731B (en)	2004-11-10
US20040054193A1 (en)	2004-03-18
US7144915B2 (en)	2006-12-05
SK16002003A3 (sk)	2004-12-01
SV2003001144A (es)	2003-03-18
AR036118A1 (es)	2004-08-11
PE20030124A1 (es)	2003-02-12
CN101215253A (zh)	2008-07-09
AU2002258092C1 (en)	2003-01-21
UA74075C2 (en)	2005-10-17
OA12636A (en)	2006-06-15
US20060241169A1 (en)	2006-10-26
JP2007182460A (ja)	2007-07-19
KR20040014583A (ko)	2004-02-14
US20080214651A1 (en)	2008-09-04
TNSN03147A1 (en)	2005-12-23
AP2003002936A0 (en)	2003-12-31
PL367943A1 (en)	2005-03-07
NO20035675D0 (no)	2003-12-18

Publication	Publication Date	Title
NO326170B1 (no)	2008-10-13	Krystallinske former av Atorvastatin
AU2002258092A1 (en)	2003-05-22	Crystalline forms of [R-(R,R)]-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US8648109B2 (en)	2014-02-11	Forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
CA2754932C (fr)	2014-04-01	Nouvelles formes de [r-(r,r)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
CA2521833C (fr)	2006-04-25	Formes cristallines de sel hemicalcique d'acide [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (2:1)(atorvastatine)
EP1957452B1 (fr)	2010-05-05	Nouvelles formes d acide [r-(r,r)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique magnesium